Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/17/2007

Net product sales increased 28% over third quarter 2006 to $177 million

SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2007. The Company reported total revenue of $190.0 million for the third quarter, including net product sales of $177.4 million. Net loss for the quarter ended September 30, 2007 was $39.8 million, or $0.30 per share. At September 30, 2007, the Company held cash, cash equivalents and short-term investments of approximately $1.1 billion.

"BYETTA and SYMLIN, our first-in-class diabetes medicines, have been on the market for nearly 30 months and continued to show growth in physician adoption, prescriptions and reported revenue in the third quarter," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. "Additionally we continued to advance our pipeline drug candidates and remain on track to report key clinical data later this quarter from our once-weekly exenatide long-acting release program and our integrated neurohormone obesity program."

Quarter ended September 30, 2007

Net product sales of $177.4 million for the third quarter include $161.1 million for BYETTA(R) (exenatide) injection and $16.3 million for SYMLIN(R) (pramlintide acetate) injection. This compares to net product sales of $138.8 million, consisting of $126.4 million for BYETTA and $12.4 million for SYMLIN for the same period in 2006.

Revenues under collaborative agreements were $12.6 million for the quarter ended September 30, 2007, compared to $8.2 million for the same period in 2006. The increase reflects higher cost-sharing payments from Lilly to equalize develo
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ...tical company focused on endocrine therapy and onc... Administration (FDA) has granted Fast Track desig...r compound, perifosine (KRX-0401), for the treatme...Biopharmaceuticals, Inc. ("Keryx") ( KERX), is AEt...
(Date:12/1/2009)...announced that he has joined Carolina Eyecare Phys... www.DrKerrySolomon.com , which was developed by M...LASIK, lens implant, and cataract surgery expert w...tantial contributions to improving vision correcti...ons, which screens LASIK surgeons based upon exper...
(Date:12/1/2009)...re/ -- Reportlinker.com announces that a new marke..., Emerging Clinical Trial Locations - Eastern ...e and regulatory environment ,, http://www.re...cations---Eastern-Europe-Market-dynamics-and-the-c... ,, Over the last decade pharmaceutical and bi...
(Date:12/1/2009)...e-Asia/ -- Shanghai ChemPartner, as the,flagship s...ntract Research,Organization (CRO), today announce...ast 50 China, ranking 3rd on the list of the faste... is a testament to ChemPartner,s outstanding,three... The results of the 2009 Deloitte Technology Fast ...
Breaking Biology Technology:AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3
... China and CARSON CITY, Nev., March 10 Niusule Bi...hat its new Venture, Niusule Bioengineering (Hangz...btaining the "Certificate of Approval for Establis...e People,s Republic of China" from Zhejiang Foreig... 2, 2009 and the Business License from Hangzhou In...
..., March 10 The following release is being issued ...Donald C. Fry, president & CEO, Greater Baltim...and researchers from the Baltimore-area bioscience...ience Awards , , WHEN: , Thursday, March 12, 2...8:45 - 9:45 a.m. / Awards Program , , WHERE: ,...
... apoB/apoAI ratio now available with VAP Cholester...., March 10 Atherotech, Inc., a cardio-diagnostic...rotein A (apoAI) to its VAP(R) Cholesterol Test. T...ngle cholesterol test that routinely reports apoAI...addition of this new marker, the VAP Test now repo...
Other Biology Technology:Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the People's Republic of China 2Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the People's Republic of China 3Greater Baltimore Committee to Announce Winners of 2009 Maryland Bioscience Awards at Ceremonies on March 12 2Greater Baltimore Committee to Announce Winners of 2009 Maryland Bioscience Awards at Ceremonies on March 12 3Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test 2Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test 3
(Date:12/2/2009)... Center researchers have figured out how stem cell...er able to resist radiation therapy. And using a d...se cancer stem cells, they were able to kill many ...xperiment. , The work builds off earlier resear...effects of radiation much better than other cancer...
(Date:12/2/2009)...identification of substances involved in the Jekyl...rine bacteria into killers that cause "coral bleac...Science & Technology , a semi-monthly journal. , ...ready has destroyed up to 30 percent of the world,...ys to slow or stop the damage. One known culprit i...
(Date:12/2/2009)...nly prescribed beta 2 adrenergic agonist drugs for... as pre-term labor may increase the incidence of a...ognitive problems and poor school performance in t...in the December 2009 issue of the American Journa...ic agonist drugs as a class are widely used in obs...
Breaking Biology News(10 mins):Discovery makes brain tumor cells more responsive to radiation 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2Retirees health care benefits at risk study warns 54809 1Retirees health care benefits at risk study warns 54809 2Retirees health care benefits at risk study warns 54809 3Scientists help explain effects of ancient Chinese herbal formulas on heart health 9612 1Scientists help explain effects of ancient Chinese herbal formulas on heart health 9612 2Par Pharmaceutical 26 Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS 28R 29 54806 1Par Pharmaceutical 26 Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS 28R 29 54806 2Par Pharmaceutical 26 Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS 28R 29 54806 3
...lifornia, San Diego, offer a new explanation for a...als found along the Malay Peninsula in southeast A...he absence of any geographical barrier. , An anci...daman Sea was once thought have split the peninsul...s to diverge. But a recent revision of the history...
...lobe dementia (Frontotemporal Dementia, FTD) strik...ease, FTD is the form of dementia that occurs most...he disease process starts in the frontal lobe wher...he frontal lobe is the foremost part of the brain ...r things, it is involved in regulating behavior, m...
...eers J. Craig Venter, Energy Bioscience Institute,...l highlight the U.S. Department of Energy Joint Ge... and Environment User Meeting March 25-27, 2009 in... emphasize the genomics of renewable energy strate...l gene discovery, and engineering of fuel-producin...
Other Biology News:New explanation for a puzzling biological divide along the Malay Peninsula 2Blood test predicts chance of dementia 2Venter, Somerville and Church highlight DOE/JGI genomics of energy and environment meeting 2
... Label IT siRNA Tracker Intracellular Localization...tly label and deliver siRNA, of your design, in an...o tracking experiments. Subcellular localization a... can be monitored following introduction of the la...
... Label IT siRNA Tracker Intracellular Localization...vides a straight forward approach to directly labe...nt yet non-destructive manner, for in vitro tracki...ional inhibition of target gene expression can be ...
...s kit allows for quick and reproducible immunoprec...e system is more reproducible than regular IPs, wh...otein A/G agarose without disrupting the agarose b... Catch and Release is reversible, and elution of t...
... Yeast Oligo Microarray Kit (V2), 2 x 11K will ena...ression of many thousands of yeast genes and ident...esses. Each microarray contains sequences represen... S288C strain of Saccharomyces cerevisiae, sourced...
Biology Products: